Control
Recent:Wang.
Aug 7 |
et al., Nature Communication, doi:0.1038/s41467-025-62214-x | The efficacy and safety of inhaled peptide YKYY017 for COVID-19 patients with mild illness: a phase 2 randomized controlled trial |
| 31% improved recovery (p=0.003) and 13% improved viral load (p=0.08). RCT 239 mostly mild COVID-19 outpatients showing the primary endpoint of viral load reduction at day 4 was not met with inhaled peptide YKYY017. The 20mg group showed significantly faster time to recovery. The study population was low-ris.. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 200,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.